- Home
- PMCB vs EVOK Comparison
PMCB vs EVOK Comparison
Compare PMCB & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- EVOK
- Stock Information
- Founded
- PMCB 1996
- EVOK 2007
- Country
- PMCB United States
- EVOK United States
- Employees
- PMCB N/A
- EVOK N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- PMCB Health Care
- EVOK Health Care
- Exchange
- PMCB Nasdaq
- EVOK Nasdaq
- Market Cap
- PMCB 6.6M
- EVOK 5.4M
- IPO Year
- PMCB N/A
- EVOK 2013
- Fundamental
- Price
- PMCB $0.94
- EVOK $5.21
- Analyst Decision
- PMCB
- EVOK
- Analyst Count
- PMCB 0
- EVOK 0
- Target Price
- PMCB N/A
- EVOK N/A
- AVG Volume (30 Days)
- PMCB 118.7K
- EVOK 437.4K
- Earning Date
- PMCB 09-12-2025
- EVOK 11-06-2025
- Dividend Yield
- PMCB N/A
- EVOK N/A
- EPS Growth
- PMCB N/A
- EVOK N/A
- EPS
- PMCB 3.19
- EVOK N/A
- Revenue
- PMCB N/A
- EVOK $12,794,859.00
- Revenue This Year
- PMCB N/A
- EVOK $57.38
- Revenue Next Year
- PMCB N/A
- EVOK $59.57
- P/E Ratio
- PMCB $0.30
- EVOK N/A
- Revenue Growth
- PMCB N/A
- EVOK 70.02
- 52 Week Low
- PMCB $0.80
- EVOK $1.94
- 52 Week High
- PMCB $2.42
- EVOK $12.32
- Technical
- Relative Strength Index (RSI)
- PMCB 47.20
- EVOK 50.12
- Support Level
- PMCB $0.92
- EVOK $5.03
- Resistance Level
- PMCB $1.00
- EVOK $5.57
- Average True Range (ATR)
- PMCB 0.09
- EVOK 0.44
- MACD
- PMCB 0.00
- EVOK -0.09
- Stochastic Oscillator
- PMCB 28.69
- EVOK 11.17
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.